US 11,786,491 B2
Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
Vincent P. Stanton, Jr., Belmont, MA (US); and Patrice P. Rioux, San Diego, CA (US)
Assigned to Thiogenesis Therapeutics, Inc., San Diego, CA (US)
Filed by Thiogenesis Therapeutics, Inc., San Diego, CA (US)
Filed on Oct. 15, 2021, as Appl. No. 17/502,427.
Application 17/502,427 is a continuation of application No. 16/084,810, granted, now 11,173,135, issued on Nov. 16, 2021, previously published as PCT/US2017/023042, filed on Mar. 17, 2017.
Claims priority of provisional application 62/309,717, filed on Mar. 17, 2016.
Prior Publication US 2022/0040127 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/16 (2006.01); A61K 31/145 (2006.01); A61K 9/50 (2006.01); A61K 9/00 (2006.01); C07C 323/52 (2006.01); C07C 323/25 (2006.01); C07F 9/6561 (2006.01); A61K 9/28 (2006.01); A61K 31/6615 (2006.01); G01N 33/50 (2006.01)
CPC A61K 31/16 (2013.01) [A61K 9/0065 (2013.01); A61K 9/0095 (2013.01); A61K 9/2846 (2013.01); A61K 9/2866 (2013.01); A61K 9/5073 (2013.01); A61K 9/5084 (2013.01); A61K 31/145 (2013.01); A61K 31/6615 (2013.01); C07C 323/25 (2013.01); C07C 323/52 (2013.01); C07F 9/65616 (2013.01); G01N 33/5023 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating a cysteamine sensitive disorder in a subject in need thereof, said method comprising administering to the subject a therapeutically-effective amount of a compound selected from pantetheine-N-acetyl-L-cysteine disulfide, pantetheine-N-acetylcysteamine disulfide, cysteamine-pantetheine disulfide, cysteamine-4-phosphopantetheine disulfide, cysteamine-gamma-L-glutamyl-L-cysteine disulfide, and cysteamine-N-acetyl-L-cysteine disulfide, and salts thereof to treat the cysteamine sensitive disorder,
wherein the cysteamine sensitive disorder is selected from Huntington's disease, Parkinson's disease, cystinosis; sickle cell disease; chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis, non-alcoholic fatty liver disease (NAFLD), Rett syndrome, and mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes (MELAS).